Roche Primes New Push Via Cipla For Avastin, Actemra In India

Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the IL-6 inhibitor, tocilizumab (Actemra), in India as they seek to expand access in a competitive, predominantly out-of-pocket market.